News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 04 - 30

CEO of Efung Capital Named to Investors.com's "2026·54 Best Young Investors" List |

Today, Investors.com officially released its "Investors.com 2026·54 Best Young Investors List". Mr. Pai Zhu, CEO of Efung Capital, stood out among numerous competitors and was named to the prestigious list, thanks to his profound industry insights and continuous deep cultivation in the biopharmaceutical field.This list is initiated by Investors.com in collaboration with the Investors Research Institute. It aims to recognize a new generation of investors who possess a unique combination of technological acumen, industrial insight, and innovative action du...

浏览次数：2

查看详情>>

发布时间: 2026 - 04 - 30

Monthly Health Reader | April 2026

On April 28, the Political Bureau of the CPC Central Committee held a meeting to analyze the economic situation and deploy work priorities. The meeting emphasized the need to implement, with precision and effectiveness, a more proactive fiscal policy and a moderately accommodative monetary policy, to boost domestic demand and drive industrial upgrading, and to strive for a good start to the 15th Five-Year Plan period. This has sent a clear signal to the market: capital will be directed toward technological innovation fields aligned with national strategies, particularly "hard tech" d...

浏览次数：0

查看详情>>

发布时间: 2026 - 04 - 29

Shensi Bio's Ultra-Long-Acting Recombinant Factor VIII FRSW117 NMPA Application Accepted

Shensi Bio announced today (April 29, 2026) that its independently developed Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (project code: FRSW117) has been submitted for marketing authorization to the National Medical Products Administration (NMPA) and has officially been accepted for review. FRSW117 is a world-first, ultra-long-acting recombinant Factor VIII product that combines two half-life extension technologies—Fc fusion and PEGylation. It is intended for routine prophylactic treatment, on-demand replacement therapy, and perioperative bleeding manage...

浏览次数：3

查看详情>>

发布时间: 2026 - 04 - 28

Ef Capital CEO Zhu Pai Receives the "2026 Top 40 Under 40 Best Direct Investment Fund Young Investor

Today, the FOF Research Center officially released its "2026 40U40 Outstanding Young Investors" rankings. Zhu Pai, CEO of Ef Capital, has been honored with the "2026 Top 40 Under 40 (40U40) Best Direct Investment Fund Young Investor" award.On the occasion of the upcoming Youth Day (May 4th), the FOF Research Center, supported by comprehensive data and in-depth research analysis, unveiled this significant ranking designed to encourage dedicated young professionals who quietly contribute to the private equity investment industry. Industry consensus traditionally holds that ta...

浏览次数：2

查看详情>>